In brief: Benitec, XRT, Phylogica, Norwood Abbey
Wednesday, 06 April, 2005
RNAi specialist Benitec (ASX:BLT) has lodged a prospectus with ASIC to raise up to AUD$9.7 million in a rights issue, underwritten by Bell Potter. Capital raised will go towards clinical development and expansion of Benitec's California operations, it said.
Unlisted imaging company XRT, an investee of BioTech Capital (ASX:BTC), has entered a deal in which an unnamed analytical company will incorporate XRT's phase contrast technology in 3D metrology and analysis instruments.
Drug discovery firm Phylogica (ASX:PYC) has named former Peptech and CSL executive Dr Greg Pullen as its chief operating officer. Most recently, Pullen was in charge of licensing at Auckland University's commercialisation entity.
Norwood Abbey (ASX:NAL) has won TGA approval for a key component of its vision correction surgery tool Epi-Lasik.
Link between oestrogen and heart health found in women
Scientists found that oestrogen helps increase the ANXA1 protein, and when ANXA1 is missing, the...
Frequent nightmares accelerate aging, increase risk of death
Nghtmares independently predict faster biological aging and earlier mortality — even after...
Cardiac organoids bring hope for treating heart disease
Australian scientists have developed lab-grown, three-dimensional heart tissues known as cardiac...
